Anticoagulation in Patients with Cancer and Venous Thromboembolism

Introduction to Anticoagulation Therapy

• The American Society of Clinical Oncology recommends the use of low molecular weight heparin (LMWH) as the anticoagulant of choice for both initial treatment (5-10 days) and long-term therapy (minimum 6 months) in patients with cancer and high risk of venous thromboembolism (VTE), with demonstrated superiority over vitamin K antagonists 1, 2, 3

Initial Treatment (First 5-10 Days)

• The American College of Chest Physicians recommends LMWH over unfractionated heparin (UFH) for initial anticoagulation in patients with cancer and newly diagnosed VTE, except in severe renal insufficiency (creatinine clearance <30 mL/min) 1, 2
• The National Comprehensive Cancer Network suggests the following initial treatment options:

Long-Term Treatment (Minimum 6 Months)

• The European Society for Medical Oncology recommends LMWH for at least 6 months to prevent recurrent VTE in patients with cancer, with superiority demonstrated over vitamin K antagonists 1, 4, 3
• The suggested treatment regimen includes:

Duration of Anticoagulation

• The American Society of Clinical Oncology recommends that the duration of anticoagulation be based on cancer activity:

Management of Recurrent VTE During Anticoagulation

• If recurrent VTE occurs despite adequate anticoagulation:

Inferior Vena Cava Filter

• Indications are limited to:

Special Considerations

• Tumors of the central nervous system: anticoagulation is recommended for established VTE, similar to other patients with cancer, with careful monitoring to limit hemorrhagic complications 1, 3
• Incidental VTE: treat similarly to symptomatic VTE with full anticoagulation 1
• Incidental visceral/splenic vein thrombosis: evaluate on a case-by-case basis, considering benefits versus risks of anticoagulation 1

Prophylaxis in Hospitalized Patients

• For hospitalized patients with cancer and additional risk factors:

Common Errors to Avoid

• Do not use warfarin as first-line treatment in patients with active cancer—LMWH is superior 1, 3
• Do not stop anticoagulation at 3 months in active cancer—minimum 6 months, consider indefinite 1, 5
• Do not place an inferior vena cava filter as first-line treatment—only for absolute contraindications 1, 3
• Do not assume that central nervous system malignancy contraindicates anticoagulation—it is safe with adequate monitoring 1, 3